Laxmi Dental Q4 FY26: A record exit quarter, with scanners and digital dentistry shaping the next phase

Laxmi Dental closed FY26 with its strongest quarter on record. Consolidated revenue from operations in Q4FY26 was INR 74.0 crore, up 21.9% year on year. Profitability also expanded sharply. EBITDA margin came in at 18.3% and PAT margin at 13.6%, even after a half-quarter impact from higher US tariffs.

The quarter mattered for another reason. Management framed FY26 as a year of external headwinds that included tariff volatility in the US, competitive pressure in domestic aligners, and a labour-code driven one-time cost. Yet the company still delivered 16.2% revenue growth for the full year, ending with a strong recovery quarter.

Q4FY26: Growth was broad-based, led by the laboratory business

The performance in Q4FY26 was driven primarily by the laboratory business. Laboratory offerings reported revenue of INR 45.9 crore, with international at INR 22.1 crore and domestic at INR 23.7 crore. Management described this as the highest-ever quarterly performance for the lab segment, supported by a recovery in India and record international revenues.

Aligner Solutions was steady at INR 18.3 crore for the quarter. Bizdent contributed INR 11.0 crore, while Vedia contributed INR 7.3 crore. Management attributed some softness in Vedia to shipment delays in March due to a sharp increase in freight costs linked to geopolitical uncertainty.

Scanner sales were INR 8.2 crore in Q4FY26. Management repeatedly described scanners as low margin but strategic, used to accelerate digital adoption and create a longer-term pipeline for lab and aligner work.

Understanding margins: scanner mix, tariffs, and one-offs

Gross margin for Q4FY26 was 70.5%, slightly higher sequentially, but below the 78.7% in Q4FY25. The key reason was mix. Scanner sales contributed more in Q4FY26 and scanners carry lower gross margins. Management clarified that gross margins for the core dental business excluding scanner sales were around 76%.

The quarter also included a half-quarter impact from higher US tariffs, estimated at 74 basis points on EBITDA margin. Management noted that the tariff situation improved later and the company was paying around 10% tariff on US exports at the time of the call, compared to a far higher level earlier.

Another margin-related factor was ESOP cost. Q4FY26 had ESOP expense of INR 0.13 crore versus INR 1.83 crore in Q4FY25. The company also recorded a tax benefit of INR 1.3 crore in Q4FY26 related to a one-time gratuity expense recognized in Q3FY26 due to changes in the labour code.

FY26: Revenue growth held up, but PAT comparisons are distorted

For FY26, consolidated revenue from operations was INR 277.9 crore, up 16.2% year on year. EBITDA margin was 15.6%, while PAT margin was 10.4%.

Management highlighted multiple items that reduce comparability. FY26 had a one-time expense of INR 5.78 crore due to a labour code related gratuity liability and higher ESOP expenses of INR 5.26 crore for the year versus INR 2.19 crore in FY25. FY25 had an exceptional gain of INR 7.03 crore from property sale, which created a higher base.

On a segment basis for FY26, laboratory offerings contributed INR 166.8 crore, aligner solutions INR 73.2 crore, and scanner sales INR 29.4 crore.

Digital dentistry playbook: scanners, penetration, and new platform launches

A consistent theme in both the investor presentation and concall was digitisation. Management stated domestic lab digital penetration is around 80% and the company is targeting over 90% digital penetration over the medium term. The strategic logic is that each scanner placed is expected to be a long-term revenue driver for laboratory and aligner workflows.

The company also launched iScope 360, described as an AI-connected remote dental platform that enables remote scanning, oral health tracking and virtual consultations. Management explained that the initial revenue model includes selling the scope device to dentists and a points-based subscription system purchased by dentists for evaluations and virtual consultations.

Balance sheet and cash flows: debt-free, but FY26 operating cash flow was negative

Management stated the company remains debt-free. The balance sheet also shows borrowings at zero as of 31-Mar-26.

However, cash flows were a key area to monitor. FY26 net cash from operating activities was negative INR 5.0 crore. Investing cash flows were negative INR 79.6 crore, including INR 65.9 crore invested in fixed deposits and mutual funds. Financing cash flows were negative INR 17.8 crore, including debt repayment. Cash and cash equivalents at year-end were INR 8.4 crore, while management stated cash and bank balances including investments were around INR 99 crore.

What investors should take away

Laxmi Dental ended FY26 with a strong Q4 recovery, supported by a sharp rebound in laboratory performance and operating leverage. The strategy is clear: expand digital workflows through scanner deployment and use the network to drive cross-selling across lab and aligners.

At the same time, risks remain visible. The business is exposed to tariff volatility in the US, freight and shipment disruptions in international supply chains, and intense competition in domestic aligners. FY26 also showed weak operating cash flow despite profitability, which makes working-capital discipline an important watch item.

The Q4 print suggests execution improved materially versus a softer Q3, but the sustainability of margins will depend on how the company balances the low-margin scanner ramp with growth in higher-margin core dental revenues.